Back | Next |
home / stock / mrkr / mrkr message board
Subject | By | Source | When |
---|---|---|---|
You mean Marker wasn't a manufacturing facility YET. | learningcurve2020 | investorshub | 05/01/2023 6:10:32 PM |
Reminds me a lot of $NWBO's Advent arrangement. | learningcurve2020 | investorshub | 05/01/2023 6:04:39 PM |
Good thing Marker's trials don't cost $100M. | Phantom Lord | investorshub | 05/01/2023 6:02:42 PM |
Given that Marker is not a manufacturing company | Phantom Lord | investorshub | 05/01/2023 6:01:20 PM |
Is this an accurate statement when trials cost | learningcurve2020 | investorshub | 05/01/2023 5:55:40 PM |
Any chance they're related? | Phantom Lord | investorshub | 05/01/2023 5:54:38 PM |
The long and winding road. | KeithamdMIC | investorshub | 05/01/2023 5:49:05 PM |
You could also interpret it as retail and | learningcurve2020 | investorshub | 05/01/2023 5:42:09 PM |
Surprised he didnt pursue a $MRKR merger with ALVR. | GMA13 | investorshub | 05/01/2023 5:40:41 PM |
Any chance they're related? Any chance Dart | learningcurve2020 | investorshub | 05/01/2023 5:37:00 PM |
PS: Meant that i jumped back in after | GMA13 | investorshub | 05/01/2023 5:28:48 PM |
If anybody wants to learn more, Wilson's email | Cincinnati Kid | investorshub | 05/01/2023 5:06:09 PM |
Funny you can't tell the difference between attacking | learningcurve2020 | investorshub | 05/01/2023 5:04:25 PM |
I do apologize to you as well , | GMA13 | investorshub | 05/01/2023 4:49:00 PM |
Attacking? Thats funny, look in the mirror, pal | jobynimble | investorshub | 05/01/2023 4:33:01 PM |
Always attacking. Big red flag. But I | learningcurve2020 | investorshub | 05/01/2023 4:26:53 PM |
I've previously said I will not be responding | Phantom Lord | investorshub | 05/01/2023 4:20:57 PM |
IMO - Mr. TPIV Wilson strikes again. He | GMA13 | investorshub | 05/01/2023 2:46:19 PM |
Anytime | jobynimble | investorshub | 05/01/2023 2:43:40 PM |
Thanks for posting all the info. I suspect | Buckboard | investorshub | 05/01/2023 2:31:41 PM |
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...